Home 主打产品 植物提取物 天然提取物 产品目录 产品解决方案 展会 联系我们
沙棘果油seabuckthorn berry oil
姜黄素Turmeric Root Extract curcumin
胡椒碱piperine
阿尔法熊果甙alpha arbutin
唾液酸sialic acid
氨基丁酸γ-aminobutyric acid
红曲米提取物Red yeast extract
红景天提取物Rhodiola Rosea Extract
苹果提取物Apple peel extract
虫草素cordycepin
紫锥菊提取物Echinacea extract
石榴皮提取物Pomegranate exract
橄榄叶提取物olive leaf extract
荷叶提取物lotus leaf extract
常春藤提取物Ivy leaf extract
积雪草提取物centella asiatic extract
羟基积雪草苷madecassoside
积雪草甙Asiaticoside
羟基积雪草酸madecassic acid
积雪草总甙Centella total glucosides
当归提取物angelica extract
大蒜提取物garlic extract
淫羊藿提取物Epimedium extract icariin
问荆提取物Horsetail extract
黄芪提取物Astragalus extract
猴头菇提取物lion's mane mushroom extract
麦苗汁粉wheat grass juice powder
绞股蓝提取物gynostemma pentaphyllum extract
覆盆子提取物raspberry extract
水飞蓟提取物milk thistle extract
灵芝提取物Reishi Mushroom Extract
人参提取物ginseng extract
大黄素Emodin

红曲米提取物Red yeast extract 

红曲米提取物

拉丁名: monascus purpureus

提取部位: seed

有效成分: 莫纳克林

含量: Monacolin K0.1%-3%, Lovastatin0.1%-3%

规格: 5:1,10:1,20

检测方式: TLC

CAS号码.:75330-75-5

外观: 红色粉末

中国传统药食两用品,用中国特有红曲霉菌在大米中发酵培养而成,已有上千年的使用历史。本品性状为红色粉末,色调纯正,光热稳定性好,纯天然,安全无副作用,PH适用范围广。

 

产品功效:

 1.具有健脾消食,活血化瘀的作用。

2.用于降血脂,降低总胆固醇,还原酶抑制剂,直接抑制HNG-coA还原酶,阻断胆固醇合成。

3.洛伐他汀(美降脂)能有效降低杂合于型家族性和非家族性高胆固醇血证患者的血清胆固醇含量。

【有效成分】:洛伐他汀(Lovastatin)
【提取溶剂】:乙醇
【过筛孔径】:80目,100目
【科属分类】曲霉科
【成分】含淀粉酶、胡萝卜色烯类。

【性味】甘、温,无毒。
【性质】系酿造中的副产品,不仅烹调食物用以着色,并入药。
【归经】肝;脾;胃;大肠经
【产品指标】:湿度小于4%重金属小于10ppm霉菌小于100cfu/g农药残留无大肠杆菌无沙门氏菌无绿脓杆菌无

产品详询:13657416805

参考文献:

  1. 1.

    Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. Executive summary: heart disease and stroke statistics–2014 update: a report from the American Heart Association. Circulation. 2014;129:399–410.

  2. 2.

    Ervin RB. Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race and ethnicity, and body mass index: United States, 2003–2006. Natl Health Stat Rep. 2009:1–7.

  3. 3.

    Misra A, Khurana L. Obesity and the metabolic syndrome in developing countries. J Clin Endocrinol Metab. 2008;93:S9–30.

  4. 4.

    Dunstan DW, Zimmet PZ, Welborn TA, De Courten MP, Cameron AJ, Sicree RA, et al. The rising prevalence of diabetes and impaired glucose tolerance. The Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care. 2002;25:829–34.

  5. 5.

    Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature. 2006;444:875–80.

  6. 6.

    Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383–93.

  7. 7.

    Expert Dyslipidemia Panel of the International Atherosclerosis Society Panel members. An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia–full report. J Clin Lipidol. 2014;8:29–60.

  8. 8.

    EFSA. Scientific Opinion on the substantiation of health claims related to monacolin K from red yeast rice and maintenance of normal blood LDL cholesterol concentrations (ID 1648, 1700) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA J. 2011;9:2304. 

  9. 9.

    Roberts CK, Sindhu KK. Oxidative stress and metabolic syndrome. Life Sci. 2009;84:705–12.

  10. 10.

    EFSA. Scientific Opinion on the substantiation of health claims related to polyphenols in olive and protection of LDL particles from oxidative damage (ID 1333, 1638, 1639, 1696, 2865), maintenance of normal blood HDL-cholesterol concentrations (ID 1639), maintenance of normal blood pressure (ID 3781), “anti-inflammatory properties” (ID 1882), “contributes to the upper respiratory tract health” (ID 3468), “can help to maintain a normal function of gastrointestinal tract” (3779), and “contributes to body defences against external agents” (ID 3467) pursuant to Article 13(1) of Regulation (EC) No 1924/20061. EFSA J. 2011;9:2033

  11. 11.

    Grundy SM, Brewer Jr HB, Cleeman JI, Smith Jr SC, Lenfant C, American Heart Association, et al. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109:433–8.

  12. 12.

    Rifai N, Warnick GR, McNamara JR, Belcher JD, Grinstead GF, Frantz Jr ID. Measurement of low-density-lipoprotein cholesterol in serum: a status report. Clin Chem. 1992;38:150–60.

  13. 13.

    Conroy RM, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24:987–1003.

  14. 14.

    Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003;326:1407–8.

  15. 15.

    Yong-Guo LI, Hong L, Zheng-Tao Wang A. validated stability-indicating HPLC with photodiode array detector (PDA) method for the stress tests of Monascus purpureus-fermented rice, red yeast rice. J Pharm Biomed Anal. 2005;39:82–90. 

  16. 16.

    Navarra T, Del Turco S, Berti S, Basta G. The lectin-like oxidized low-density lipoprotein receptor-1 and its soluble form: cardiovascular implications. J Atheroscler Thromb. 2010;17:317–31.

  17. 17.

    Tsimikas S, Miller YI. Oxidative modification of lipoproteins: mechanisms, role in inflammation and potential clinical applications in cardiovascular disease. Curr Pharm Des. 2011;17:27–37.

  18. 18.

    EFSA Panel on Dietetic Products, Nutrition and Allergies. Guidance on the scientific requirements for health claims related to antioxidants, oxidative damage and cardiovascular health. EFSA J. 2011;9:2474.

  19. 19.

    Nauck M, Warnick GR, Rifai N. Methods for measurement of LDL-cholesterol: a critical assessment of direct measurement by homogeneous assays versus calculation. Clin Chem. 2002;48:236–54.

  20. 20.

    Mancini GB, Baker S, Bergeron J, Fitchett D, Frohlich J, Genest J, et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference. Can J Cardiol. 2011;27:635–62.

  21. 21.

    Bogsrud MP, Ose L, Langslet G, Ottestad I, Strøm EC, Hagve TA, et al. HypoCol (red yeast rice) lowers plasma cholesterol - a randomized placebo controlled study. Scand Cardiovasc J. 2010;44:197–200. doi:10.3109/14017431003624123.

  22. 22.

    Verhoeven V, Lopez Hartmann M, Remmen R, Wens J, Apers S, Van Royen P. Red yeast rice lowers cholesterol in physicians - a double blind, placebo controlled randomized trial. BMC Complement Altern Med. 2013;13:178.

  23. 23.

    Chen CH, Yang JC, Uang YS, Lin CJ. Improved dissolution rate and oral bioavailability of lovastatin in red yeast rice products. Int J Pharm. 2013;444:18–24

  24. 24.

    Venero CV, Venero JV, Wortham DC, Thompson PD. Lipid-lowering efficacy of red yeast rice in a population intolerant to statins. Am J Cardiol. 2010;105:664–6.

  25. 25.

    Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest. 2004;114:1752–61.

  26. 26.

    Keaney Jr JF, Larson MG, Vasan RS, Wilson PW, Lipinska I, Corey D, et al. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol. 2003;23:434–9.

  27. 27.

    Grattagliano I, Palmieri VO, Portincasa P, Moschetta A, Palasciano G. Oxidative stress-induced risk factors associated with the metabolic syndrome: a unifying hypothesis. J Nutr Biochem. 2008;19:491–504.

  28. 28.

    Van Guilder GP, Hoetzer GL, Greiner JJ, Stauffer BL, Desouza CA. Influence of metabolic syndrome on biomarkers of oxidative stress and inflammation in obese adults. Obesity (Silver Spring). 2006;14:2127–31.

  29. 29.

    Holvoet P, Lee DH, Steffes M, Gross M, Jacobs Jr DR. Association between circulating oxidized low-density lipoprotein and incidence of the metabolic syndrome. JAMA. 2008;299:2287–93.

  30. 30.

    Wierzbicki AS, Clarke RE, Viljoen A, Mikhailidis DP. Triglycerides: a case for treatment? Curr Opin Cardiol. 2012;27:398–404.

  31. 31.

    Ballantyne CM, Raichlen JS, Cain VA. Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin) trial. J Am Coll Cardiol. 2008;52:626–32.

  32. 32.

    Psaltopoulou T, Naska A, Orfanos P, Trichopoulos D, Mountokalakis T, Trichopoulou A. Olive oil, the Mediterranean diet, and arterial blood pressure: the Greek European Prospective Investigation into Cancer and Nutrition (EPIC) study. Am J Clin Nutr. 2004;80:1012–8.

  33. 33.

    Gilani AH, Khan AU, Shah AJ, Connor J, Jabeen Q. Blood pressure lowering effect of olive is mediated through calcium channel blockade. Int J Food Sci Nutr. 2005;56:613–20.

  34. 34.

    Doménech M, Roman P, Lapetra J, de la Corte FJ G, Sala-Vila A, de la Torre R. Mediterranean diet reduces 24-hour ambulatory blood pressure, blood glucose, and lipids: one-year randomized, clinical trial. Hypertension. 2014;64:69–76.

  35. 35.

    Toledo E, Hu FB, Estruch R, Buil-Cosiales P, Corella D, Salas-Salvadó J, et al. Effect of the Mediterranean diet on blood pressure in the PREDIMED trial: results from a randomized controlled trial. BMC Med. 2013;11:207. doi:10.1186/1741-7015-11-207.

  36. 36.

    Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011;305:2556–64.

  37. 37.

    Matikainen N, Taskinen MR. Management of dyslipidemias in the presence of the metabolic syndrome or type 2 diabetes. Curr Cardiol Rep. 2012;14:721–31.

  38. 38.

    Yinhua L, Long J, Zhangrong J, Wei X, Shiwei Y, Qiu Y, et al. A meta-analysis of red yeast rice: an effective and relatively safe alternative approach for Dyslipidemia. PLoS One. 2014;9:e98611.

  39. 39.

    Becker DJ, Gordon RY, Halbert SC, French B, Morris PB, Rader DJ. Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial. Ann Intern Med. 2009;150:830–9.

  40. 40.

    Lapi F, Gallo E, Bernasconi S, Vietri M, Menniti-Ippolito F, Raschetti R, et al. Myopathies associated with red yeast rice and liquorice: spontaneous reports from the Italian Surveillance System of Natural Health Products. Br J Clin Pharmacol. 2008;66:572–4.

  41. 41.

    Mueller PS. Symptomatic myopathy due to red yeast rice. Ann Intern Med. 2006;145:474–5.

  42. 42.

    Gordon RY, Cooperman T, Obermeyer W, Becker DJ. Marked variability of monacolin levels in commercial red yeast rice products: buyer beware! Arch Intern Med. 2010;170:1722–7.

  43. 43.

    Li YG, Zhang F, Wang ZT, Hu ZB. Identification and chemical profiling of monacolins in red yeast rice using high-performance liquid chromatography with photodiode array detector and mass spectrometry. J Pharm Biomed Anal. 2004;35:1101–12.

  44. 44.

    Hsin-Ping O, Wang C-CR, Lih-Shiuh L. Thermal degradation kinetics analysis of monacolin K in Monascus-fermentated products LWT. Food Sci Technol. 2009;42:292–6.


Home  |  主打产品  |  植物提取物  |  天然提取物  |  产品目录  |  产品解决方案  |  展会  |  联系我们  |  网站地图  |  手机版
  English     简体版     繁體版
网站首页联系我们网站地图